FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression

Sternberg, CN; Petrylak, DP; Bellmunt, J; Nishiyama, H; Necchi, A; Gurney, H; Lee, JL; van der Heijden, MS; Rosenbaum, E; Penel, N; Pang, ST; Li, JR; del Muro, XG; Joly, F; Pápai, Z; Bao, WC; Ellinghaus, P; Lu, CX; Sierecki, M; Coppieters, S; Nakajima, K; Ishida, TC; Quinn, DI

Quinn, DI (通讯作者)，USC Norris Comprehens Canc Ctr, Dept Med, Div Oncol, 1441 Eastlake Ave,Ste 3440, Los Angeles, CA 90033 USA.

JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (3): 629

Abstract

PURPOSE Rogaratinib, an oral pan-fibroblast growth factor receptor (FGFR1-4) inhibitor, showed promising phase I efficacy and safety in patients with ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索